How do I buy Vanda Pharmaceuticals Inc (VNDA) stock?

Buying Vanda Pharmaceuticals Inc (VNDA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "VNDA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy VNDA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if VNDA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Vanda Pharmaceuticals Inc (VNDA) Stock

NMQ · VNDA

Trade VNDA

Fundamentals

Market cap

$259.99M

Price / Earnings ratio

-1.0x

Price / Sales ratio

1.3x

Price / Book ratio

1.3x

Return on assets

-57.0%

Dividend amount

$0.00

Dividend yield

0.00%

Source: third-party data provider, as of October 14, 2026

Compare with VNDA

Technical indicators

RSI 14: 26.95
MACD 12/26/9: -0.21
EMA 9 of MACD: -0.17
MACD histogram: -0.04
SMA 50: $5.09; Price below SMA 50
EMA 50: $5.08; Price below EMA 50
SMA 200: $6.45; Price below SMA 200
EMA 200: $5.94; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Buy

Based on 3 analyst ratings

Strong Sell0

Sell0

Hold0

Buy3

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2025

259M171M86M0

Debt & Balance Sheet

Total assets

Total liabilities

2025

587M387M194M0

Revenue to Profit

2025

$216.1M

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-220.5M

Net income

Earnings

EPS forecast

Actual EPS

$-1.67

Q4FY25

$-0.36

Q1FY26

$-0.19

Q2FY26

The market is expecting earnings per share of -$0.19 for this quarter. The company has not yet shared when it is announcing earnings.

Source: third-party data provider

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

SectorHealthcare

IndustryBiotechnology

Employees533

CEODr. Mihael H. Polymeropoulos M.D.

IPO DateApr 12, 2006

HeadquartersWashington, DC

Key Executives

Name	Title	Year Born
Dr. Mihael H. Polymeropoulos M.D.	Founder, President, CEO & Chairman of The Board	1960
Mr. Kevin Patrick Moran	Senior VP, CFO & Treasurer	1984
Mr. Joakim Wijkstrom	Senior VP & Chief Marketing Officer	1966
Mr. Gunther Birznieks	Senior Vice President of Business Development	1969
Mr. Daniel Patrick McGuire	Senior VP, General Counsel & Secretary	—
Mr. Scott L. Howell	Chief People Officer	1975
Mr. Christos Polymeropoulos M.D.	Senior Vice President & Medical Director	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021										-7.0	-16.0	-1.6
2022	-8.4	-25.3	-0.4	-16.1	-3.8	+11.8	-3.7	+0.4	-8.6	+3.5	+2.5	-32.6
2023	+3.5	-16.0	+5.3	-10.2	-7.5	+11.7	-10.1	-8.0	-15.5	+5.0	-14.9	+8.2
2024	-20.4	+19.8	-10.8	+15.5	+7.1	+10.4	+4.7	-6.2	-7.7	+2.4	+10.5	-5.0
2025	-8.5	+10.4	-2.8	+0.2	-2.3	+9.8	-9.0	+12.9	+5.9	-14.7	+19.9	+75.7
2026	-8.6	+15.1	-15.4	+0.4	-7.9	-3.9	-15.7	+3.3	-9.4	-10.6

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Vanda Pharmaceuticals Inc (VNDA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "VNDA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy VNDA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Vanda Pharmaceuticals Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Vanda Pharmaceuticals Inc (VNDA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track VNDA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Vanda Pharmaceuticals Inc (VNDA) Stock

Fundamentals

Compare with VNDA

Recent news

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates

Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know

Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug

Incyte (INCY) Beats Q1 Earnings and Revenue Estimates

Incyte (INCY) Beats Q1 Earnings and Revenue Estimates

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections

About Vanda Pharmaceuticals Inc

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade